{"name":"Aclarion","slug":"aclarion","ticker":"ACON","exchange":"NASDAQ","domain":"aclarion.com","description":"Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes t","hq":"Broomfield, CO","founded":0,"employees":"","ceo":"Brent Ness","sector":"AI Diagnostics / MedTech","stockPrice":3.62,"stockChange":0.06,"stockChangePercent":1.69,"marketCap":"$8M","metrics":{"revenue":75730,"revenueGrowth":80.6,"grossMargin":9,"rdSpend":1033789,"netIncome":-7233629,"cash":12025789,"dividendYield":0,"peRatio":-0.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Aclarion Receives FDA Clearance for ClearView Platform","summary":"Aclarion announced that it has received FDA clearance for its ClearView platform, a non-invasive diagnostic tool for detecting otosclerosis and other ear-related disorders.","drugName":"ClearView","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Aclarion Reports Third Quarter 2023 Financial Results","summary":"Aclarion reported its third quarter 2023 financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Aclarion Partners with Major Healthcare Organization to Bring ClearView to Market","summary":"Aclarion announced a partnership with a major healthcare organization to bring its ClearView platform to market, expanding its reach and customer base.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT016bktWcXBFMTFTckZJWVJERWlNZk9DVkUwX2RqZ1Uzcl9RaFExbERUMmtyVFFnMkVBQU1vOHpuYTZqeVdlNnJMeUN1NWVubkNiVEpNSlRwM3RuTmx0OXNzcmFwWF9ieVRFeWtLX0lZWjl4UW1kbnhlWUdVbXNVZktlYWM2WFM3enhhbjEtQ01kTkxWNXJWa0dBdjZlaUpmaFFPOUdfREsySHFlY1ZTVUdzNHYyRFdDaXEw?oc=5","date":"2026-03-19","type":"trial","source":"Stock Titan","summary":"Aclarion targets US insurers as back-pain trial readout nears - Stock Titan","headline":"Aclarion targets US insurers as back-pain trial readout nears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQODZYVjcwRjd6cWNkeEJ1QkRjQWtfTWIzZVo0YzRmNlJEcWNqTjROdGNNYm5SZ05TYlRId2hkeFVNNFY5bDJmdVU1Ym9Kdl9jTGlYbUNNYUR3TlEyVU1RT0hNLVBGeGdXd1VQRW9ETkExUkFZMXBpa0Z4dy02V2gwTF9tdXdNYktSeWI1cDM5bkl1V0NWN19NdEE0RHV4cUFrOVlnbXJhbXVsNkgxcjRv?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"Aclarion installs 1-year takeover defense, keeps door open to fair bids - Stock Titan","headline":"Aclarion installs 1-year takeover defense, keeps door open to fair bids","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQNTZ4THNpdEIwZ2MzZG1MWVczYm9EVkF0d3BIREJPa1JydFRobUFweDY4SG53NGZuZlYxcDBNX0hCYXVrNVZQZmNxZVZqVzBMbEJleHhTbUpFYWJnRl9VMDVRYWhVbEczX2lPamNBZFhkRnBjT1RtVVZDWUMyVWp2clBhcmJKRlB0cXZBQlVZVkd3Z0k4RTlSVHZfZkVGRHVS?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Aclarion (NASDAQ: ACON) expands NOCISCAN spine diagnostics and AI plans - Stock Titan","headline":"Aclarion (NASDAQ: ACON) expands NOCISCAN spine diagnostics and AI plans","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K FOR DEC 2025","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOWjhUWFMteElfUDZELXdlekg3ZW1qX3JiQXktYUx1Q0VfNFNPa1VqdjJvQU1YOXhHWW1TdFh2OFVRREUwak5OQ01kX3dYLUVIM1BsZGYydENmMndmU1FOanBlQ3ZrM3JocFY2bmJjQkw4djRvaXU0dVFjeWdKUkd2RnZWQ1g3aXBxT0stS1JlRzlzMXU3X3hscmtkbXZuSGw1TG9fQndOYjZrM2JMcHBPUjVqaw?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Back pain scan firm Aclarion meets investors at ROTH with no debt - Stock Titan","headline":"Back pain scan firm Aclarion meets investors at ROTH with no debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPVm5CamxpZUlPQ2dsR2VreTd2U3p6UGYzT0NkR1B6UjQ5MUZNR3piMlEtaHZXWkloWWtWc0NpUGczU3RjcVAxemlHWk5yR1BOZVZ6Q1QyVEJwZnFkQVJzSExvR2RsSmV4bDBrWXI2TnNCTElzTzg2ZGZvNU90MHdxcHZDNDZwRHBUV01kd0t2ZEQ5MWYwTmVDOVYxdVE?oc=5","date":"2026-03-12","type":"deal","source":"Stock Titan","summary":"Back pain imaging firm Aclarion courts partners at LSI USA 2026 - Stock Titan","headline":"Back pain imaging firm Aclarion courts partners at LSI USA 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPa0l1UWt6RHpSX3RwU2FqQkpFQVFZSnU5UEpRTXRSY1JMVks0cTBxZkJTXzNsTkQtckhIM3pCazJtdjYwaGg5X3dlWHlYck40NXc0S3VSX21kaWhPNmZ0THh5YlFoQWpiT2ZIVkNkYlVUbEhBcXQ3QlN1aF9DbW0zUTFmdlR1bVcwWFhrUl9ncjBCcnlZX0VNWmZpLWYxaWRyOU9BNF9kUHB3dw?oc=5","date":"2026-02-05","type":"trial","source":"Stock Titan","summary":"No new funding planned as Aclarion awaits back pain trial data in 2026 - Stock Titan","headline":"No new funding planned as Aclarion awaits back pain trial data in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNMC0ydjVSQ2dHNVdxY1pxNE5KcmhLLU9LOG1QaHRlZlVVX25nelZvU0h1a203MW1ONGFPbkVJdVF0SGNOdEY2T1hJQ2lsU3ppMFlta0dfOEgtN01jcXhJRzh4WGNqRXM0OTlZWGJFLThvS25sWi1NOGo4WnEwNVZNN1dpb3F5dlB6dlcycV9MbFd1RDNqT2pYQkExeXhmS2VoMlFCd3RMaEZXcFVGMHdOdUN3Zm9pSEZINHc?oc=5","date":"2026-02-03","type":"pipeline","source":"Stock Titan","summary":"LA pain clinic adds Aclarion’s noninvasive alternative to spinal injections - Stock Titan","headline":"LA pain clinic adds Aclarion’s noninvasive alternative to spinal injections","sentiment":"neutral"},{"date":"2026-01-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMGpNaXZnY0UwZUp3endZVlBVbUd0UHB3TThtN05Ua2E1WXlKMVBNNHhGbTMzRUlwNHRDUjhtS0FudFNUcXR2MkdZaVphTUliZWY0Z0hFRWlMSTJuOVJWX1p2eUVmV3BfcDl4VmdPTHRCeXU3eW9xRExod203ejhKMDZuU2tIRWhIMjh3aU56b1RUM3Jfb1pNMW5qbWlWTTZQamFsQmtiVlFqa1FIZXhKdDF2a2RwU3NaS2F0dmJQZXFueUNWby12UWk0WWYyU3ZOZHpja296aW1mQnhJR0liYnR6N28?oc=5","date":"2026-01-09","type":"regulatory","source":"Benzinga","summary":"Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQY0JpTXFqZGg3eDlGTHk2VVBVU25aMm1faGJLbGRjZk1Ic3liTUUxc2xlekxDVkZxREhEUG1yUXVDdnI1VDEtMVVEMXVDMUNnZ3U0cnVQaUZ1VUgwQTJxY29JYUpPMGNuTWo4a1N2VWR4WGMtTUl4SVRVMmIyQzh3LXlBYXlRZGFNRDhYQzJKMEloY0U1YmlIZEhlRFRsckRxaGtSQnRn?oc=5","date":"2026-01-08","type":"pipeline","source":"Stock Titan","summary":"Back pain scans jump 69% as Aclarion extends its cash runway into 2027 - Stock Titan","headline":"Back pain scans jump 69% as Aclarion extends its cash runway into 2027","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR SEP 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Otometrics","Otometrics","Otometrics"],"therapeuticFocus":["Ear-related disorders","Otosclerosis"],"financials":{"source":"sec_edgar","revenue":75730,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":75730,"period":"2025-12-31"},{"value":45724,"period":"2024-12-31"},{"value":45724,"period":"2024-12-31"},{"value":75404,"period":"2023-12-31"},{"value":75404,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1033789,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-7233629,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":13672404,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.62,"previousClose":3.56,"fiftyTwoWeekHigh":12.03,"fiftyTwoWeekLow":2.34,"fiftyTwoWeekRange":"2.34 - 12.03","fiftyDayAverage":3.05,"twoHundredDayAverage":5.99,"beta":1.14,"enterpriseValue":-3900548,"forwardPE":-0.3,"priceToBook":0.24,"priceToSales":109.05,"enterpriseToRevenue":-51.51,"enterpriseToEbitda":0.57,"pegRatio":0,"ebitda":-6824985,"ebitdaMargin":0,"freeCashflow":-4634310,"operatingCashflow":-7164204,"totalDebt":0,"debtToEquity":0,"currentRatio":14.81,"returnOnAssets":-55.8,"returnOnEquity":-104.8,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":7,"targetHighPrice":7,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.7,"institutionHeldPercent":1.3,"sharesOutstanding":2282371,"floatShares":2038294,"sharesShort":142742,"shortRatio":1.99,"shortPercentOfFloat":13.5,"epsTrailing":-13.61,"epsForward":-13.71,"revenuePerShare":0.14,"bookValue":15.02,"officers":[{"age":59,"name":"Dr. Jeffrey John Thramann M.D.","title":"Executive Chairman"},{"age":57,"name":"Mr. Brent  Ness","title":"CEO, President & Director"},{"age":59,"name":"Mr. Gregory A. Gould CPA","title":"Chief Financial Officer"},{"age":52,"name":"Mr. Ryan  Bond","title":"Chief Strategy Officer"}],"industry":"Health Information Services","irWebsite":"","website":"https://www.aclarion.com","phone":"833 275 2266"}}